Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,intangibleAssets,capitalSurplus,totalLiab,totalStockholderEquity,deferredLongTermLiab,otherCurrentLiab,totalAssets,commonStock,otherCurrentAssets,retainedEarnings,otherLiab,otherAssets,cash,totalCurrentLiabilities,propertyPlantEquipment,totalCurrentAssets,longTermInvestments,netReceivables,inventory,accountsPayable,changeToLiabilities,totalCashflowsFromInvestingActivities,changeToOperatingActivities,changeInCash,totalCashFromOperatingActivities,depreciation,changeToInventory,changeToAccountReceivables,changeToNetincome,capitalExpenditures,investments,WC,language,region,quoteType,triggerable,quoteSourceName,regularMarketChangePercent,regularMarketDayRange,regularMarketPreviousClose,messageBoardId,fullExchangeName,longName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,currency,esgPopulated,tradeable,market,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,marketState,shortName,exchange,epsTrailingTwelveMonths,exchangeDataDelayedBy,bookValue,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,twoHundredDayAverageChangePercent,marketCap,priceToBook,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,gmtOffSetMilliseconds,priceHint,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,Shares Short 4,Short Ratio 4,Short % of Float 4,Short % of Shares Outstanding 4,Shares Short (prior month ) 4,Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,longBusinessSummary,city,phone,state,compensationAsOfEpochDate,country,website,maxAge,address1,fax,industry,address2
t0,HXBM,1054524.0,165718,133009,,-785184,,-785184,926100,333832,-748173,-748173,,-50673,,,,0,469071,1217244,135239,-37011,,-785184,-785184,95470.0,49192432.0,551928.0,1149994.0,150917.0,69569.0,1701922.0,49721.0,201040.0,-48092159.0,32258.0,159439.0,216534.0,519670.0,19602.0,1210072.0,217339.0,397500.0,330989.0,321565.0,196857.0,-10731.0,79438.0,-522574.0,-511843.0,22896.0,-35405.0,-60760.0,19642.0,-10731.0,,690402.0,en-US,US,EQUITY,False,Delayed Quote,0.0,24.8 - 24.8,24.8,finmb_413088,Other OTC,"Helix BioMedix, Inc.",USD,21,71,0.0,0.0,24.8 - 25.1,-0.30000114,-0.011952236,24.8,25.1,USD,False,False,us_market,24.8,1630086452,0.0,24.8,24.8,24.8,100,PRE,HELIX BIOMEDIX INC,PNK,-15.589,0,6.939,24.8,0.0,0.0,24.8,0.0,0.0,7125883,3.5740018,15,America/New_York,EDT,-14400000,2,-0.02,,,25.1,24.8,24.8,24.8,21,71,165.72k,,,,,,,,,,,,,,,0.00%,,,1:300,"Jan 02, 2013","Dec 30, 2011","Sep 29, 2012",-125.06%,-117.30%,-59.00%,-122.53%,2.07M,12.47,18.80%,1.16M,-2.33M,-2.58M,-15.59,,216.53k,1.31,,,2.33,6.94,-1.82M,-1.08M,Value,98021,Healthcare,8,"Helix BioMedix, Inc. operates as a specialty dermatology and consumer products skin health company in the United States. It develops and commercializes bioactive peptides, including anti-infective, anti-fungal, and anti-inflammatory peptides for the treatment of skin and wound infections, as well as for the prevention of staphylococcus aureus infections. The company also out-licenses its proprietary peptides to various entities. Helix BioMedix, Inc. was founded in 1988 and is headquartered in Bothell, Washington.",Bothell,425-402-8400,WA,1325289600,United States,http://www.helixbiomedix.com,86400,22121-17th Avenue SE,425-806-2999,Biotechnology,Suite 112
t-1,HXBM,1789595.0,165718,87942,,-668299,,-668299,780081,306065,-584021,-584021,,-50123,,,,0,470522,1054543,164457,-84278,,-668299,-668299,112412.0,49159261.0,330889.0,1902007.0,201590.0,91661.0,2232896.0,49721.0,201040.0,-47306975.0,23995.0,211257.0,739108.0,306894.0,14825.0,1691737.0,202665.0,336740.0,295584.0,110957.0,-120969.0,-27000.0,-98872.0,-424426.0,-397426.0,22063.0,27307.0,323349.0,67872.0,-10731.0,-27000.0,1384843.0,en-US,US,EQUITY,False,Delayed Quote,0.0,24.8 - 24.8,24.8,finmb_413088,Other OTC,"Helix BioMedix, Inc.",USD,21,71,0.0,0.0,24.8 - 25.1,-0.30000114,-0.011952236,24.8,25.1,USD,False,False,us_market,24.8,1630086452,0.0,24.8,24.8,24.8,100,PRE,HELIX BIOMEDIX INC,PNK,-15.589,0,6.939,24.8,0.0,0.0,24.8,0.0,0.0,7125883,3.5740018,15,America/New_York,EDT,-14400000,2,-0.02,,,25.1,24.8,24.8,24.8,21,71,165.72k,,,,,,,,,,,,,,,0.00%,,,1:300,"Jan 02, 2013","Dec 30, 2011","Sep 29, 2012",-125.06%,-117.30%,-59.00%,-122.53%,2.07M,12.47,18.80%,1.16M,-2.33M,-2.58M,-15.59,,216.53k,1.31,,,2.33,6.94,-1.82M,-1.08M,Value,98021,Healthcare,8,"Helix BioMedix, Inc. operates as a specialty dermatology and consumer products skin health company in the United States. It develops and commercializes bioactive peptides, including anti-infective, anti-fungal, and anti-inflammatory peptides for the treatment of skin and wound infections, as well as for the prevention of staphylococcus aureus infections. The company also out-licenses its proprietary peptides to various entities. Helix BioMedix, Inc. was founded in 1988 and is headquartered in Bothell, Washington.",Bothell,425-402-8400,WA,1325289600,United States,http://www.helixbiomedix.com,86400,22121-17th Avenue SE,425-806-2999,Biotechnology,Suite 112
t-2,HXBM,2407619.0,165718,87085,,-581838,,-581838,906904,470891,-546193,-546193,,-12117,,,,0,680422,1226615,209531,-35645,,-581838,-581838,129354.0,49125928.0,511906.0,2536973.0,251713.0,145959.0,3048879.0,49721.0,201040.0,-46638676.0,26328.0,265977.0,1163534.0,485578.0,19946.0,2427995.0,205607.0,660089.0,322891.0,177035.0,55080.0,-27000.0,1665.0,-525411.0,-525411.0,23095.0,40978.0,-219381.0,142873.0,-10731.0,-27000.0,1942417.0,en-US,US,EQUITY,False,Delayed Quote,0.0,24.8 - 24.8,24.8,finmb_413088,Other OTC,"Helix BioMedix, Inc.",USD,21,71,0.0,0.0,24.8 - 25.1,-0.30000114,-0.011952236,24.8,25.1,USD,False,False,us_market,24.8,1630086452,0.0,24.8,24.8,24.8,100,PRE,HELIX BIOMEDIX INC,PNK,-15.589,0,6.939,24.8,0.0,0.0,24.8,0.0,0.0,7125883,3.5740018,15,America/New_York,EDT,-14400000,2,-0.02,,,25.1,24.8,24.8,24.8,21,71,165.72k,,,,,,,,,,,,,,,0.00%,,,1:300,"Jan 02, 2013","Dec 30, 2011","Sep 29, 2012",-125.06%,-117.30%,-59.00%,-122.53%,2.07M,12.47,18.80%,1.16M,-2.33M,-2.58M,-15.59,,216.53k,1.31,,,2.33,6.94,-1.82M,-1.08M,Value,98021,Healthcare,8,"Helix BioMedix, Inc. operates as a specialty dermatology and consumer products skin health company in the United States. It develops and commercializes bioactive peptides, including anti-infective, anti-fungal, and anti-inflammatory peptides for the treatment of skin and wound infections, as well as for the prevention of staphylococcus aureus infections. The company also out-licenses its proprietary peptides to various entities. Helix BioMedix, Inc. was founded in 1988 and is headquartered in Bothell, Washington.",Bothell,425-402-8400,WA,1325289600,United States,http://www.helixbiomedix.com,86400,22121-17th Avenue SE,425-806-2999,Biotechnology,Suite 112
t-3,HXBM,2389039.0,165718,75913,,-548350,,-548350,756429,313908,-545000,-545000,,-12117,,,,0,445900,990900,131992,-3350,,-548350,-548350,146297.0,48542453.0,439303.0,2535336.0,,141997.0,2974639.0,49721.0,,-46056838.0,28660.0,20884.0,1688945.0,410643.0,26098.0,2558105.0,223255.0,440708.0,363869.0,125324.0,12647.0,6000.0,41513.0,-378317.0,-384317.0,26566.0,-7782.0,70343.0,20746.0,-10731.0,-27000.0,2147462.0,en-US,US,EQUITY,False,Delayed Quote,0.0,24.8 - 24.8,24.8,finmb_413088,Other OTC,"Helix BioMedix, Inc.",USD,21,71,0.0,0.0,24.8 - 25.1,-0.30000114,-0.011952236,24.8,25.1,USD,False,False,us_market,24.8,1630086452,0.0,24.8,24.8,24.8,100,PRE,HELIX BIOMEDIX INC,PNK,-15.589,0,6.939,24.8,0.0,0.0,24.8,0.0,0.0,7125883,3.5740018,15,America/New_York,EDT,-14400000,2,-0.02,,,25.1,24.8,24.8,24.8,21,71,165.72k,,,,,,,,,,,,,,,0.00%,,,1:300,"Jan 02, 2013","Dec 30, 2011","Sep 29, 2012",-125.06%,-117.30%,-59.00%,-122.53%,2.07M,12.47,18.80%,1.16M,-2.33M,-2.58M,-15.59,,216.53k,1.31,,,2.33,6.94,-1.82M,-1.08M,Value,98021,Healthcare,8,"Helix BioMedix, Inc. operates as a specialty dermatology and consumer products skin health company in the United States. It develops and commercializes bioactive peptides, including anti-infective, anti-fungal, and anti-inflammatory peptides for the treatment of skin and wound infections, as well as for the prevention of staphylococcus aureus infections. The company also out-licenses its proprietary peptides to various entities. Helix BioMedix, Inc. was founded in 1988 and is headquartered in Bothell, Washington.",Bothell,425-402-8400,WA,1325289600,United States,http://www.helixbiomedix.com,86400,22121-17th Avenue SE,425-806-2999,Biotechnology,Suite 112
